Skip to main content
Clinical Trials/NCT05382195
NCT05382195
Unknown
Not Applicable

Clinical Correlates of Psychiatric Comorbidities in Patients With Multiple Sclerosis

Sohag University1 site in 1 country100 target enrollmentJune 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Patients With Multiple Sclerosis
Sponsor
Sohag University
Enrollment
100
Locations
1
Primary Endpoint
anxiety in patients with multiple sclerosis
Last Updated
3 years ago

Overview

Brief Summary

Many neuropsychiatric abnormalities associated with multiple sclerosis (MS). These may be broadly divided into 2 categories: disorders of mood, affect,and behavior and abnormalities affecting cognition. With respect to the former, theepidemiology, phenomenology, and theories of etiology are described for the syndromes ofdepression, bipolar disorder, euphoria, pathological laughing and crying, and psychosisattributable to MS.

Finally,treatment pertaining to all these disorders is reviewed, with the observation thattranslational research has been found wanting when it comes to providing algorithms toguide clinicians. Guidelines derived from general psychiatry still largely apply, althoughthey may not always be most effective in patients with neurologic disorders.

The importance of future research addressing this imbalance is emphasized, forneuropsychiatric sequel add significantly to the morbidity associated with MS.(1) The evolution of the neuropsychiatry of multiple sclerosis(MS), with a set sequence of events unfoldingoverthecourseofacenturyormore,providesahistoricalparadigmforotherneurologicdisorders.Accordingtotheparadigm,aclinically astute neurologist, whom posterity will treat kindly,first describes the neurologic (and occasionally, the psycho-logical) signs and symptomsthat cometo define the disorder.

Over succeeding decades, the diagnostic criteria arerefined by further observation supplemented by data fromnew technologies. Mental state changes either pass with littlenoticeoraremissed.Acoupleofgenerationslatercomes belated recognition of prominent abnormalities in mentation-neuropsychiatryredux.

. Invariably, the data reveal major psychiatric problems integral to the disease, and then, with fewexceptions, clinical research stops. Few double-blind,placebo-controlled treatment trials in neuropsychiatry provide an evidence-based approach to treating the newly discernedbehaviouralabnormalities.

ThelifetimeprevalenceofmajordepressioninMS isapproximately 50% (2). A meta-analysis suggests that this is higherthan in other neurologic disorders (3) and, depending on thereferencepoint,is3to10 timestherateinthegeneral population (4). While the basic phenomenology of the MS depressive syndrome overlaps with that found in primarydepression, certain symptoms are more typical, while othersoccur less commonly. Thus, irritability, discouragement, andasenseoffrustration aremorelikelytoaccompanylowmoodthan are feelings of guilt and poor self-esteem (5). It is alsoimportanttorememberthatsymptomssuchasinsomnia,poorappetite,anddifficultieswithconcentrationandmemorymaybe equally attributable to depression or to MS.

Depression is an important reason for so many MS patients'thoughtsofself-harm:suicidalintentoccursinapproximately30% of MS patients and is linked to the presence and severityof depression and social isolation (

Registry
clinicaltrials.gov
Start Date
June 1, 2022
End Date
February 1, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Esraa Mamdouh Ramadan

resident doctor at Neuropsyiatric department faculty of medicine sohag university

Sohag University

Eligibility Criteria

Inclusion Criteria

  • The diagnosis of MS will be established clinically from the history according to revised McDonald's criteria 2010 The following psychiatric disorders ;depression , anxiety fulfilling the diagnostic criteria according to DSM5 as regard therapy, in the out patient clinic of Neuropsychiatry at Sohag university hospital from 1-6-2022 to 1-2-2023

Exclusion Criteria

  • Any patient with the following will be excluded from the study
  • diagnosis of m.s is not definite
  • vitally un stable
  • refused consent

Outcomes

Primary Outcomes

anxiety in patients with multiple sclerosis

Time Frame: 8 months

hospital anxiety and depression scale a questionaire of anxiety from 0to 21

depression in patients with multiple sclerosis

Time Frame: 8 months

hospital anxiety and depression scale a questionaire of depression from 0 to 21

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Exploring the Comorbidity Between Mental Disorders and General Medical ConditionsOrganic, Including Symptomatic, Mental DisordersSubstance UseSchizophreniaMood [Affective] DisordersNeurotic, Stress-related and Somatoform DisordersEating DisorderDisorders of Adult Personality and BehaviorMental RetardationDisorder of Psychological DevelopmentBehavioural DisorderHypertensionDyslipidemiasIschemic Heart DiseaseAtrial FibrillationHeart FailurePeripheral Occlusive DiseaseStrokeDiabetes MellitusThyroid DisorderGoutChronic Pulmonary DiseaseAllergyChronic GastritisChronic Liver DiseaseInflammatory Bowel DiseasesDiverticular Disease of Large IntestineChronic Kidney DiseasesProstate DisordersConnective Tissue DisorderOsteoporosisPainHIV/AIDSAnemiaCancerVision DisordersHearing DisordersMigraineEpilepsyParkinson DiseaseMultiple SclerosisNeuropathy
NCT03847753University of Aarhus5,940,299
Recruiting
Not Applicable
MEDICAL ILLNESS IN MENTAL DISORDERS
CTRI/2013/08/003890FATHER MULLER CHARITABLE INSTITUTIONS1,000
Completed
Not Applicable
Assessment of Patients With Multiple Sclerosis (MS)Herpesviridae InfectionHTLV-I InfectionMultiple SclerosisTropical Spastic ParaparesisVasculitis
NCT00001156National Institute of Neurological Disorders and Stroke (NINDS)1,388
Recruiting
Not Applicable
Multimodal Exploration of Patients With Multiple Sclerosis for an Early Detection of Subtle ProgressionMultiple Sclerosis
NCT05941975Brugmann University Hospital60
Completed
Not Applicable
Effects of the Cross-Training in Patients With Multiple SclerosisMultiple SclerosisWeaknessFatigue
NCT02010398Università degli Studi di Sassari45